Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise

ConclusionTreatment of acquired TTP in the U.S. remains heterogeneous. Points of clinical equipoise identified were PV exchanged (1.0 vs >1.0), tapering of TPE versus none, and rituximab use.

Source: Journal of Clinical Apheresis - October 1, 2017 Category: Hematology Authors: Marshall A. Mazepa, Jay S. Raval, Mark E. Brecher, Yara A. Park Tags: RESEARCH ARTICLE Source Type: research